{"id":275158,"date":"2026-09-28T14:08:01","date_gmt":"2026-09-28T08:38:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=275158"},"modified":"2026-09-28T14:08:01","modified_gmt":"2026-09-28T08:38:01","slug":"morepen-laboratories-share-price-anda","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/","title":{"rendered":"Morepen Files Its First US ANDA for Sitagliptin, and the Stock Gains 2.5% as It Builds Beyond APIs"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Morepen Labs Rs 123.37, up 2.48% (28 Sep, 1:50 PM). First US ANDA: Sitagliptin. CDMO deal Rs 825 crore. P\/E 46.87 vs industry 38.42. ROE 5.96%.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Morepen Laboratories share price was Rs 123.37 at 1:50 PM on 28 September 2026, up 2.48 percent, after the company submitted its first Abbreviated New Drug Application to the US FDA for Sitagliptin tablets in 25 mg, 50 mg and 100 mg strengths. The filing extends Morepen from active ingredients and contract manufacturing into finished dosage forms and regulatory submissions. An ANDA filing is not an approval, and the FDA review can take many months. The stock trades at a P\/E of 46.87 against an industry figure of 38.42, with a return on equity of only 5.96 percent.<\/p>\n<\/div>\n<p>Morepen Laboratories Limited said it has submitted its first ANDA to the US Food and Drug Administration, for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths. The company described the submission as an extension of its established API and CDMO expertise into integrated finished dosage development and regulatory filing.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=morepen-laboratories-share-price-anda\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>The Morepen Laboratories share price touched Rs 126.22 and traded on volume about 1.3 times its five-day average. This article looks at the filing, the CDMO order behind the recent rally and the risks for the Morepen Laboratories share price.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#What_the_First_ANDA_Filing_Means_for_Morepen\" title=\"What the First ANDA Filing Means for Morepen\">What the First ANDA Filing Means for Morepen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Morepen_Laboratories_Share_Price_Today_Numbers_and_Technical_Levels\" title=\"Morepen Laboratories Share Price Today: Numbers and Technical Levels\">Morepen Laboratories Share Price Today: Numbers and Technical Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#The_CDMO_Order_Behind_the_Morepen_Laboratories_Share_Price\" title=\"The CDMO Order Behind the Morepen Laboratories Share Price\">The CDMO Order Behind the Morepen Laboratories Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Valuation_and_Risks_for_the_Morepen_Laboratories_Share_Price\" title=\"Valuation and Risks for the Morepen Laboratories Share Price\">Valuation and Risks for the Morepen Laboratories Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#What_is_the_Morepen_Laboratories_share_price_today\" title=\"What is the Morepen Laboratories share price today?\">What is the Morepen Laboratories share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#What_ANDA_has_Morepen_filed\" title=\"What ANDA has Morepen filed?\">What ANDA has Morepen filed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Does_the_ANDA_filing_mean_approval\" title=\"Does the ANDA filing mean approval?\">Does the ANDA filing mean approval?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#How_does_the_ANDA_change_the_Morepen_Laboratories_share_price_outlook\" title=\"How does the ANDA change the Morepen Laboratories share price outlook?\">How does the ANDA change the Morepen Laboratories share price outlook?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#What_is_Morepens_CDMO_deal\" title=\"What is Morepen&#8217;s CDMO deal?\">What is Morepen&#8217;s CDMO deal?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#What_are_the_key_technical_levels_for_the_Morepen_Laboratories_share_price\" title=\"What are the key technical levels for the Morepen Laboratories share price?\">What are the key technical levels for the Morepen Laboratories share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Is_the_Morepen_Laboratories_share_price_expensive\" title=\"Is the Morepen Laboratories share price expensive?\">Is the Morepen Laboratories share price expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/morepen-laboratories-share-price-anda\/#Should_I_buy_Morepen_shares_after_the_ANDA_news\" title=\"Should I buy Morepen shares after the ANDA news?\">Should I buy Morepen shares after the ANDA news?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_the_First_ANDA_Filing_Means_for_Morepen\"><\/span><strong>What the First ANDA Filing Means for Morepen<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Item<\/th>\n<th style=\"text-align:left;\">Detail<\/th>\n<\/tr>\n<tr>\n<td>Filing<\/td>\n<td>Abbreviated New Drug Application to the US FDA<\/td>\n<\/tr>\n<tr>\n<td>Product<\/td>\n<td>Sitagliptin Tablets USP<\/td>\n<\/tr>\n<tr>\n<td>Strengths<\/td>\n<td>25 mg, 50 mg and 100 mg<\/td>\n<\/tr>\n<tr>\n<td>Significance<\/td>\n<td>First US ANDA for the company<\/td>\n<\/tr>\n<tr>\n<td>Status<\/td>\n<td>Submitted, not approved<\/td>\n<\/tr>\n<\/table>\n<p>Morepen has long made active pharmaceutical ingredients and supplied other drug makers. Filing its own ANDA moves it up the value chain into finished tablets, which is the long-term story behind the Morepen Laboratories share price, where margins can be higher than in ingredients but competition and regulatory work are heavier.<\/p>\n<p>A filing starts a review, and approval timelines are uncertain, so the news is a step in strategy rather than an earnings event for the Morepen Laboratories share price.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/nifty-below-23000\">Nifty Slips Below 23,000 as Sensex Tests Its Support Zone: What Drove the Selloff and What to Watch<\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Morepen_Laboratories_Share_Price_Today_Numbers_and_Technical_Levels\"><\/span><strong>Morepen Laboratories Share Price Today: Numbers and Technical Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Metric<\/th>\n<th style=\"text-align:left;\">Value (28 Sep, 1:50 PM)<\/th>\n<\/tr>\n<tr>\n<td>Morepen Laboratories share price<\/td>\n<td>Rs 123.37 (up 2.48%)<\/td>\n<\/tr>\n<tr>\n<td>Previous close<\/td>\n<td>Rs 120.38<\/td>\n<\/tr>\n<tr>\n<td>Day range<\/td>\n<td>Rs 119.45 to Rs 126.22<\/td>\n<\/tr>\n<tr>\n<td>Volume so far<\/td>\n<td>1.49 crore shares<\/td>\n<\/tr>\n<tr>\n<td>Five-day average volume<\/td>\n<td>1.15 crore shares<\/td>\n<\/tr>\n<tr>\n<td>RSI (14-day)<\/td>\n<td>54.6<\/td>\n<\/tr>\n<tr>\n<td>MACD vs signal line<\/td>\n<td>7.89 vs 8.85<\/td>\n<\/tr>\n<tr>\n<td>SuperTrend<\/td>\n<td>Bullish, support at Rs 98.92<\/td>\n<\/tr>\n<tr>\n<td>20-day average<\/td>\n<td>Rs 116.21<\/td>\n<\/tr>\n<tr>\n<td>Market cap (Friday close)<\/td>\n<td>Rs 6,600 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E vs industry P\/E<\/td>\n<td>46.87 vs 38.42<\/td>\n<\/tr>\n<\/table>\n<p>The Morepen Laboratories share price is 6.2 percent above its 20-day average of Rs 116.21, and the RSI of 54.6 is neutral. The MACD line is just below its signal line, so momentum is flat, and the SuperTrend indicator shows support at Rs 98.92.<\/p>\n<p>Volume of about 1.3 times the five-day average shows some interest in the Morepen Laboratories share price, though the stock has traded in a narrow Rs 116 to Rs 127 range over the past week.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Pharma Stocks and Live Levels on the Univest Screener<\/strong><\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"The_CDMO_Order_Behind_the_Morepen_Laboratories_Share_Price\"><\/span><strong>The CDMO Order Behind the Morepen Laboratories Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In February 2026 Morepen won a multi-year CDMO mandate worth about Rs 825 crore, or USD 91 million, from a global pharma company, and the stock rose more than 15 percent that day. The company completed a first commercial dispatch of about Rs 50 crore in Q1 FY27.<\/p>\n<p>It expects additional supplies of around Rs 225 crore in Q2 FY27, subject to customer schedules and regulatory and commercial requirements. The company has also reported a USFDA inspection at its Himachal API facility with zero observations, which supports its standing with global customers.<\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Valuation_and_Risks_for_the_Morepen_Laboratories_Share_Price\"><\/span><strong>Valuation and Risks for the Morepen Laboratories Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The stock trades at a P\/E of 46.87 against an industry figure of 38.42, with a return on equity of 5.96 percent and a price to book of 5.30. Debt to equity is a low 0.17, but the valuation asks investors to pay for growth that has not yet appeared in returns.<\/p>\n<p>Delivery is the first risk for the Morepen Laboratories share price, since the CDMO revenue depends on customer schedules. Regulatory outcomes are the second: an ANDA may face questions or delays, and any such delay would weigh on the Morepen Laboratories share price. The company must also show that new finished-dose work can earn returns above its current level of 5.96 percent on equity, since the market is already paying a premium multiple. Competition in generic sitagliptin is the third, and it could limit pricing.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/us-iran-peace-talks-oil-price\">Trump Rejects Iran&#8217;s Peace Proposal: Oil Climbs, the Dollar Firms and Gold Falls as Rate-Hike Bets Build<\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Morepen Laboratories share price and get alerts on filings and orders.<\/em><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Morepen Laboratories share price of Rs 123.37 reflects a small gain after its first US ANDA, a strategic step that is not yet an approval or a revenue source. The Rs 825 crore CDMO order and a low debt to equity of 0.17 are supports for the Morepen Laboratories share price, while a P\/E of 46.87 with a return on equity of 5.96 percent leaves little cushion. Investors deciding whether to buy Morepen shares should watch the Rs 98.92 support, follow stop-loss levels and consult a SEBI-registered adviser.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_the_Morepen_Laboratories_share_price_today\"><\/span><strong>What is the Morepen Laboratories share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Morepen Laboratories share price was Rs 123.37 at 1:50 PM on 28 September 2026, up 2.48 percent from Rs 120.38. The day high is Rs 126.22.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_ANDA_has_Morepen_filed\"><\/span><strong>What ANDA has Morepen filed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Morepen submitted its first ANDA to the US FDA for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Does_the_ANDA_filing_mean_approval\"><\/span><strong>Does the ANDA filing mean approval?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. It starts the FDA review, which can take many months, and approval is not assured.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"How_does_the_ANDA_change_the_Morepen_Laboratories_share_price_outlook\"><\/span><strong>How does the ANDA change the Morepen Laboratories share price outlook?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It signals a move into finished dosage forms, which could lift margins in future, but the Morepen Laboratories share price will depend on approval and launch timing.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_Morepens_CDMO_deal\"><\/span><strong>What is Morepen&#8217;s CDMO deal?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In February 2026 the company won a multi-year CDMO mandate worth about Rs 825 crore from a global pharma company and began commercial dispatch in Q1 FY27.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_are_the_key_technical_levels_for_the_Morepen_Laboratories_share_price\"><\/span><strong>What are the key technical levels for the Morepen Laboratories share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key levels for the Morepen Laboratories share price are SuperTrend support at Rs 98.92 and the 20-day average of Rs 116.21. The RSI is 54.6.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Is_the_Morepen_Laboratories_share_price_expensive\"><\/span><strong>Is the Morepen Laboratories share price expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The P\/E of 46.87 is above the industry figure of 38.42 and return on equity is 5.96 percent, so the valuation is at a premium.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Should_I_buy_Morepen_shares_after_the_ANDA_news\"><\/span><strong>Should I buy Morepen shares after the ANDA news?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The filing is a positive step but not an approval, and the valuation is high. Use a stop-loss and consult a SEBI-registered adviser.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Morepen Laboratories share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Morepen Laboratories share price was Rs 123.37 at 1:50 PM on 28 September 2026, up 2.48 percent from Rs 120.38. The day high is Rs 126.22.\"}},{\"@type\":\"Question\",\"name\":\"What ANDA has Morepen filed?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Morepen submitted its first ANDA to the US FDA for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths.\"}},{\"@type\":\"Question\",\"name\":\"Does the ANDA filing mean approval?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. It starts the FDA review, which can take many months, and approval is not assured.\"}},{\"@type\":\"Question\",\"name\":\"How does the ANDA change the Morepen Laboratories share price outlook?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It signals a move into finished dosage forms, which could lift margins in future, but the Morepen Laboratories share price will depend on approval and launch timing.\"}},{\"@type\":\"Question\",\"name\":\"What is Morepen's CDMO deal?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In February 2026 the company won a multi-year CDMO mandate worth about Rs 825 crore from a global pharma company and began commercial dispatch in Q1 FY27.\"}},{\"@type\":\"Question\",\"name\":\"What are the key technical levels for the Morepen Laboratories share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The key levels for the Morepen Laboratories share price are SuperTrend support at Rs 98.92 and the 20-day average of Rs 116.21. The RSI is 54.6.\"}},{\"@type\":\"Question\",\"name\":\"Is the Morepen Laboratories share price expensive?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of 46.87 is above the industry figure of 38.42 and return on equity is 5.96 percent, so the valuation is at a premium.\"}},{\"@type\":\"Question\",\"name\":\"Should I buy Morepen shares after the ANDA news?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The filing is a positive step but not an approval, and the valuation is high. Use a stop-loss and consult a SEBI-registered adviser.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Morepen filed its first US ANDA for Sitagliptin and the stock rose 2.5%. Here is what it means, the CDMO order behind the rally and the risks.<\/p>\n","protected":false},"author":34,"featured_media":275157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[1007,1019],"class_list":["post-275158","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-pharma-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["275157"],"rank_math_title":["Morepen Laboratories Share Price Rises on First US ANDA Filing"],"rank_math_description":["Morepen Laboratories share price is Rs 123.37, up 2.48%, after its first US ANDA for Sitagliptin tablets. CDMO order, valuation, technical levels and risks explained."],"rank_math_focus_keyword":["Morepen Laboratories share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/morepen-files-its-first-us-anda-for-sitagliptin-and-the-stock-gains-2-5-as-it.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/275158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=275158"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/275158\/revisions"}],"predecessor-version":[{"id":275159,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/275158\/revisions\/275159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/275157"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=275158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=275158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=275158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}